|Bid||139.72 x 800|
|Ask||0.00 x 1000|
|Day's Range||141.72 - 144.70|
|52 Week Range||110.51 - 170.75|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||23.15|
|Earnings Date||Oct 27, 2020|
|Forward Dividend & Yield||2.96 (2.08%)|
|Ex-Dividend Date||Nov 12, 2020|
|1y Target Est||165.07|
Mirati Therapeutics will be widely-watched as it updates Phase 1 results for a lung cancer treatment that would compete against an important product in the pipeline from Amgen. Other early trial results will be reported.
NEW YORK, NY / ACCESSWIRE / October 23, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE:LLY).
Until vaccines end the Covid pandemic, analysts expect billions of dollars in annual sales for treatments and other remedies.